SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Ambrx Biopharma Inc. (AMAM) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 28/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AMAM
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio146.04
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-2.02
Book Value / Share$0.00
Revenue / Share$0.19
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.59 |
$10.31M |
$-22.31M |
-216.4% |
| 2020 |
$-0.47 |
$13.67M |
$-17.84M |
-130.5% |
| 2021 |
$-3.34 |
$7.46M |
$-68.29M |
-916% |
| 2022 |
$-2.02 |
$7.4M |
$-78M |
-1053.7% |
